Cureus
July 1, 2025
Akshita Suleria, Sakshi Verma, Khanij Arya et al.
Lysergic acid diethylamide (LSD) is an ergot-derived psychedelic agent that produces perceptual and psychic effects of heightened sensations by acting on the dopaminergic, adrenergic, and serotonergic pathways in the brain and periphery, with 5-hydroxytryptamine 2A (5-HT2A) as the primary target molecule. Its action on these receptors in the central nervous system is comparatively well studied...
Veterinary medicine and science
July 1, 2025
Elisa Hernández-Álvarez, Lucas F Borkel, Jaime Rojas-Hernández et al.
3 citations
This pilot study explored the potential of microdosing 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) to treat canine anxiety. A single-case study was conducted on a 13-year-old female dog with severe separation anxiety, who was treated with 5 µg of 1cp-LSD every 3 days for a month. Anxiety was assessed before, after, and 1 month following treatment using a validated questionnaire. The...
medRxiv
June 18, 2025
Drummond E-Wen Mcculloch, Kristian Larsen, Annette Johansen et al.
preprint
In this study, we provide the first study to integrate molecular and functional neuroimaging during psychedelic drug effects in humans. Using simultaneous PET-MRI technology, we describe multiple brain actions of lysergic acid diethylamide (LSD) in healthy volunteers. We quantify the occupancy of LSD at cerebral serotonin 2A receptors and show that LSD increases global cerebral blood flow and...
bioRxiv Preprint Server
June 16, 2025
Beatriz de S. Carrilho, Aline Duarte, Isabelle Martins et al.
preprint
Aging is modulated by nutrient-sensing pathways that integrate metabolic and hormonal cues to regulate growth, stress resilience, and lifespan. Caloric restriction (CR), a well-established intervention, extends longevity in diverse species through modulation of conserved nutrient-sensing pathways, including TOR signaling. Lysergic acid diethylamide (LSD), a classic serotonergic psychedelic with...
bioRxiv : the preprint server for biology
June 15, 2025
Michael Von Gunten, Tenna Russell, Isaac Stirland et al.
preprint
Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potential mechanism underlying their therapeutic benefits may involve a reversal of maladaptive plasticity induced by drug exposure. Here, we identify physiological, behavioral, and epigenetic impacts of lysergic acid diethylamide (LSD) on morphine-treated...
Pharmaceutics
June 11, 2025
Bernard Do, Luc Mallet, Maxime Annereau et al.
Background/Objectives: D-lysergic acid diethylamide (D-LSD) is under investigation as a potential therapeutic strategy for alcohol use disorder (AUD). However, the extreme light sensitivity of D-LSD presents a significant challenge in developing suitable pharmaceutical forms, particularly for clinical trial settings. This study proposes a liquid-filled capsule formulation designed to provide...
Med
June 4, 2025
Felix Müller, Hannes Zaczek, Anna M Becker et al.
21 citations
This trial aimed to assess the efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with moderate-to-severe major depressive disorder. This was a randomized, parallel, double-blind, low-dose controlled trial (Clinicaltrials.gov: NCT03866252). Patients were randomly assigned in a 1:1 ratio to receive supportive psychotherapy and either 100 μg + 200 μg LSD or 25 μg + 25 μg...
Psychedelic Medicine
June 1, 2025
Rahul Katkar, Ashley M Perez, Murat Altinay et al.
4 citations
Gender-themed lysergic acid diethylamide (LSD) experiences have been documented anecdotally but not yet studied systematically. This study aimed to explore such experiences using data from Reddit to better understand their nature and potential therapeutic implications. In this retrospective observational study, posts and comments on the "r/LSD" subreddit reporting gender-themed LSD experiences...
JAMA Psychiatry
June 1, 2025
Lorenz Mueller, Joyce Santos de Jesus, Yasmin Schmid et al.
14 citations
Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD's efficacy in reducing ADHD symptoms remains unknown. To determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with placebo. This...
Clinical Pharmacology & Therapeutics
May 26, 2025
Denis Arikci, Friederike Holze, Lorenz Mueller et al.
6 citations
Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent. Additionally, LSD's absolute oral bioavailability is unknown. Therefore, we tested the bioequivalence of...